Cargando…
Class I HDAC Inhibition Leads to a Downregulation of FANCD2 and RAD51, and the Eradication of Glioblastoma Cells
HDAC inhibitors (HDACi) hold great potential as anticancer therapies due to their ability to regulate the acetylation of both histone and non-histone proteins, which is frequently disrupted in cancer and contributes to the development and advancement of the disease. Additionally, HDACi have been sho...
Autores principales: | Drzewiecka, Małgorzata, Jaśniak, Dominika, Barszczewska-Pietraszek, Gabriela, Czarny, Piotr, Kobrzycka, Anna, Wieczorek, Marek, Radek, Maciej, Szemraj, Janusz, Skorski, Tomasz, Śliwiński, Tomasz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532614/ https://www.ncbi.nlm.nih.gov/pubmed/37763083 http://dx.doi.org/10.3390/jpm13091315 |
Ejemplares similares
-
Histone Deacetylases (HDAC) Inhibitor—Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor
por: Drzewiecka, Małgorzata, et al.
Publicado: (2023) -
Synthetic Lethality Targeting Polθ
por: Drzewiecka, Małgorzata, et al.
Publicado: (2022) -
Polθ Inhibition: An Anticancer Therapy for HR-Deficient Tumours
por: Barszczewska-Pietraszek, Gabriela, et al.
Publicado: (2022) -
Eradication of LIG4-deficient glioblastoma cells by the combination of PARP inhibitor and alkylating agent
por: Toma, Monika, et al.
Publicado: (2018) -
FANCI-FANCD2 stabilizes the RAD51-DNA complex by binding RAD51 and protects the 5′-DNA end
por: Sato, Koichi, et al.
Publicado: (2016)